Adaptive Biotechnologies Corp (NASDAQ: ADPT) shares surged 5.23% in pre-market trading on Thursday, following the company's impressive third-quarter financial results and a series of analyst upgrades.

The biotechnology firm reported quarterly adjusted earnings of 6 cents per share, significantly beating the analyst consensus estimate of a 15-cent loss. This marks a substantial improvement from the 22-cent loss reported in the same quarter last year. Revenue also exceeded expectations, reaching $93.97 million, a 102.4% increase year-over-year and well above the anticipated $64.64 million.

In response to the strong performance, several Wall Street analysts raised their price targets for Adaptive Biotechnologies. JP Morgan increased its target from $17 to $20, while TD Cowen boosted its projection from $18 to $22. The positive sentiment is reflected in the current average analyst rating of "buy," with 7 out of 8 analysts recommending either "strong buy" or "buy." The median 12-month price target now stands at $17.00, slightly above the last closing price of $16.92. This wave of optimism has contributed to the stock's impressive 182.2% gain year-to-date, underlining investor confidence in the company's growth trajectory and market potential in the biotechnology sector.